Aug 22, 2025 • Zacks Commentary
NEUTRAL
NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.
Aug 11, 2025 • Zacks Commentary
BULLISH
LeMaitre ( LMAT ) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Aug 06, 2025 • Motley Fool
SOMEWHAT-BULLISH
LeMaitre ( LMAT ) Q2 Revenue Jumps 15%
LeMaitre Vascular ( NASDAQ:LMAT ) , a medical device company focused on vascular surgeons, reported its latest quarterly earnings after the bell on August 5, 2025. The company delivered GAAP results ahead of expectations, posting GAAP earnings per share of $0.60, above the anticipated $0.57 ( ...
Aug 05, 2025 • Zacks Commentary
NEUTRAL
LeMaitre Vascular ( LMAT ) Beats Q2 Earnings and Revenue Estimates
LeMaitre (LMAT) delivered earnings and revenue surprises of +5.26% and +2.53%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 04, 2025 • Zacks Commentary
BULLISH
PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?
PAHC vs. LMAT: Which Stock Is the Better Value Option?
Jun 10, 2025 • Benzinga
SOMEWHAT-BULLISH
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors - LeMaitre Vascular ( NASDAQ:LMAT ) , Anteris Technologies Glb ( NASDAQ:AVR )
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 ( GLOBE NEWSWIRE ) -- Anteris Technologies Global Corp. ( Anteris or the Company ) AVRAVR ) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, ...